Request for regulatory guidance for cancer cachexia intervention trials.
Request for regulatory guidance for cancer cachexia intervention trials.
复制标题
癌症恶病质干预试验的监管指南请求。
DOI：
10.1002/jcsm.12083
复制
发表时间：
2015-12
期刊：
影响因子：
--
通讯作者：
Anker SD
中科院分区：
文献类型：
--
作者：
Fearon K;Argiles JM;Baracos VE;Bernabei R;Coats A;Crawford J;Deutz NE;Doehner W;Evans WJ;Ferrucci L;Garcia JM;Gralla RJ;Jatoi A;Kalantar-Zadeh K;Lainscak M;Morley JE;Muscaritoli M;Polkey MI;Rosano G;Rossi-Fanelli F;Schols AM;Strasser F;Vellas B;von Haehling S;Anker SD
罗马不是一天建成的。同样，如果考虑全身性抗癌治疗的演变，从接受任何治疗到实现孤立肿瘤反应（不延长生存期）的单一药物到目前使用联合方案作为手术辅助治疗，需要几十年的时间。癌症恶病质和骨骼肌萎缩是一个重要的临床问题，对大部分癌症患者来说，这是一个高医疗需求的问题，并且与非常差的生活质量和非常高的死亡率有关。1，2在确定一个全面的多模式策略以改善患者的生活质量和数量之前，一个复杂的多因素综合征（如恶病质）的有效治疗可能会从一系列的发现和新的干预措施中发展出来。3
Rome was not built in a day. Likewise, if one considers the evolution of systemic anti-cancer treatment, it took decades to go from acceptance of any therapy at all to single agents achieving isolated tumour responses (without prolongation of survival) to the current use of combination regimens as adjuvant therapy to surgery. Such incremental progress has led to improved quality of life and eventually survival for patients with some types of cancer.Cachexia and skeletal muscle wasting in cancer are significant clinical problems of high medical need for a large proportion of cancer patients and associated with very poor quality of life and very high mortality. 1, 2 An effective treatment of a complex multifactorial syndrome such as cachexia will likely evolve from a series of steps of discovery and new interventions before a comprehensive multimodal strategy can be identified that improves patient’s quality and quantity of life. 3